Ardsley Advisory Partners LP Raises Stock Holdings in argenex SE $ARGX

Ardsley Advisory Partners LP increased its position in shares of argenex SE (NASDAQ:ARGX) by 60.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,000 shares of the company’s stock after acquiring an additional 9,000 shares during the period. argenex comprises about 2.2% of Ardsley Advisory Partners LP’s portfolio, making the stock its 7th biggest position. Ardsley Advisory Partners LP’s holdings in argenex were worth $20,183,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ARGX. M&T Bank Corp increased its stake in shares of argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after buying an additional 774,916 shares during the period. Sands Capital Management LLC raised its stake in argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after buying an additional 340,245 shares during the period. Wellington Management Group LLP raised its stake in argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the period. Two Sigma Investments LP raised its stake in shares of argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of argenex in the fourth quarter worth approximately $188,071,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Up 1.6%

NASDAQ ARGX opened at $892.26 on Thursday. The stock’s 50-day simple moving average is $820.36 and its two-hundred day simple moving average is $810.81. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a market capitalization of $55.49 billion, a price-to-earnings ratio of 39.73, a PEG ratio of 1.34 and a beta of 0.47.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, equities analysts expect that argenex SE will post 26.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. HC Wainwright increased their price objective on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Citizens Jmp increased their price objective on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Royal Bank Of Canada cut their price target on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Finally, Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.